The IOZK is a translational center and develops immuno-oncological procedures on the basis of new scientific findings.
These are combined in the best possible way for each individual patient. For this reason, no randomized clinical trials are conducted at the IOZK. These require the same treatment protocol for all patients in the experimental group and a comparison group that does not receive any treatment. In science, new research methods are being developed and discussed that are better suited to investigating the effectiveness of a highly individualized therapy. It is very important to us to contribute to scientific progress and the development of modern immunotherapy against tumor diseases.
Here we provide scientific papers published by IOZK employees.
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
New IOZK publication on liquid biopsy
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Stefaan van Gool is editor of a special issue in the Journal of Molecular Sciences
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
Impaired DNA repair in mouse monocytes compared to macrophages and precursors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
IOZK analysis proves good tolerability of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience